Skip to main content
logo
BioInfra Co., Ltd. (KOSDAQ:199730)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,755.00
-45.00 (-0.94%)
Last updated: Nov 18, 2025, 10:50 AM KST

Revenue by Product

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Phase 1 Clinical Trial
12.46B
Log In
Log In
Log In
Log In
Bioequivalence Testing
9.76B
Log In
Log In
Log In
Log In
Clinical / Non-clinical Sample Analysis
1.19B
Log In
Log In
Log In
Log In
Sample Analysis for Not Licensing Purposes, etc.
325.77M
Log In
Log In
Log In
Log In
Non-approved Clinical Trials
34.71M
Log In
Log In
Log In
Log In
Clinical Trials for Approval
22.01M
Log In
Log In
Log In
Log In
Other
36.94M
Log In
Log In
Log In
Log In
Clinical Trials and New Drug Specimen Analysis
-
Log In
Log In
Log In
Log In
Clinical Trials and New Drug Specimen Analysis Growth
-
Log In
Log In
Log In
Log In

Revenue by Geography

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
South Korea
23.83B
Log In
Log In
Log In
Log In
South Korea Growth
-20.90%
Log In
Log In
Log In
Log In